April 1, 2019 – New York, NY – Wall Street Reporter, the leading name in financial news since 1843, has recently published interviews with CEO’s of some of today’s most talked about biotech and healthcare stocks. These interviews are available in audio and video at www.WallStreetReporter.com
CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D.
Dr. Pourhassan discusses CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer. The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019.
Dr. Pourhassan explains the PRO140 technology, its numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer.
FREE public access to the complete 23 minute CEO interview (VIDEO) is available at:
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) CEO Interview with James F. Oliviero discussing clinical progress in company’s pipeline of cancer drugs, addressing multi-billion dollar markets. The company’s lead drug is in late stage clinical trials, with potential commercialization within next 3 years.
The complete 26 minute CEO interview is available for paid subscribers at:
Generex Biotechnology Corp. (OTC: GNBT) Interview with CEO Joe Moscato. Joe shares an update on the continued transformation of Generex into a next-generation integrated pharmaceutical healthcare business, through strategic acquisitions. Joe Moscato outlines the corporate growth strategy, which is focused on strategic acquisitions of revenue-generating healthcare assets, including: services, pharmaceuticals and medical devices.
The complete 28 minute CEO interview is available for paid subscribers at:
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Interview with Roger Tung, CEO discussing the company’s deuterium chemistry platform for creating new drugs which have superior properties—including enhanced clinical safety, tolerability or efficacy—based on compounds that have established pharmacological activity.
The complete 26 minute CEO interview is available for paid subscribers at:
DID YOU KNOW:
– Shares of BOSS have increased +260% since the original December 20, 2018 CEO Interview from $0.20 to a recent high of C$0.72.
– Shares of NGTF have increased +360% since the original January 11, 2019 CEO Interview from $0.20 to a recent high of 0.92.
– Shares of GNBT have increases 90% since the original January 11, 2019 interview from $1.60 to a subsequent high of $3.05
Shouldn’t you be a subscriber to Wall Street Reporter and get in on the ground floor of WINNING STOCKS like these? We focus on companies at key inflection points, and undergoing positive material change, which can drive stock prices higher within 3-6 months.
It’s no wonder that WallStreetReporter.com is the best kept secret amongst top-performing hedge-funds, family offices, and sophisticated investors worldwide.
Join here: https://www.wallstreetreporter.com/subscribe/
ABOUT:
Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO’s of promising, publicly-traded companies, and market experts.
Wall Street Reporter’s global investor audience consists primarily of hedge fund managers, investment advisors, analysts, investment bankers, and self-directed individual investors managing over $2 trillion in capital worldwide.
https://www.wallstreetreporter.com/subscribe/
CONTACT:
WALL STREET REPORTER
590 Madison Avenue
21st Floor
New York, NY 10022
(212) 871-2057 ext 7
DISCLAIMER: Free public access to their CEO interview, is sponsored GWPD, NGTF, BOSQF which was originally posted in members-only and available for paid subscribers only. Editorial policy: Our interviews are produced as editorial content available for access to paid subscribers. Post-interview, companies have the option of sponsoring their interview, to enable free public access.Rule17b updated disclosures available at